Celyad SA, a clinical-stage biopharmaceutical company, focuses on engineered cell therapy treatments. It develops therapeutic therapies for the treatment of unmet medical needs in cardiology and oncology. The company's best known product is the C-Cure, an autologous cell therapy for the treatment of heart failure. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.